Latest / Glaucoma, Vision & Longevity: Supplements & Science / Aspartame, Sucralose, Saccharin, and Stevia: Comparative Mechanistic Plausibility in Glaucoma

Transcript

Aspartame, Sucralose, Saccharin, and Stevia: Comparative Mechanistic Plausibility in Glaucoma · Glaucoma, Vision & Longevity: Supplements & Science

• 0:00
  SPEAKER_00: Aspartame, sucralose, saccharin, and stevia.
• 0:03
  SPEAKER_00: Comparative Mechanistic Plausibility in Glaucoma.
• 0:06
  SPEAKER_00: Introduction.
• 0:07
  SPEAKER_00: People with glaucoma often ask whether diet drinks, artificial sweeteners, or stevia could damage the optic nerve.
• 0:14
  SPEAKER_00: The question is biologically reasonable because glaucoma is not only an eye pressure disorder.
• 0:19
  SPEAKER_00: Retinal ganglion cell injury can also involve vascular dysregulation, impaired endothelial function, oxidative stress, mitochondrial dysfunction, blood retinal barrier changes, and chronic neuroinflammation.
• 0:32
  SPEAKER_00: However, a biologically plausible pathway is not the same as a demonstrated clinical risk.
• 0:38
  SPEAKER_00: At present, there is no established human evidence that ordinary consumption of aspartame, sucralose, saccharin, or purified stevial glycosides causes glaucoma or accelerates glaucoma dysprogression.
• 0:50
  SPEAKER_00: The available evidence is mainly regulatory toxicology, absorption studies, metabolic research, cell experiments, animal studies, and research on cardiovascular or inflammatory outcomes rather than glaucoma itself.
• 1:04
  SPEAKER_00: Existing glaucoma nutrition reviews do not identify these sweeteners as proven glaucoma risk factors.
• 1:10
  SPEAKER_00: The most defensible conclusion is therefore, for typical intake within established safety limits, all four sweeteners are more likely to be neutral with respect to glaucoma than directly harmful or beneficial.
• 1:23
  SPEAKER_00: The main potential benefit is indirect.
• 1:26
  SPEAKER_00: Replacing sugar-sweetened foods or beverages may reduce glucose-related vascular stress.
• 1:31
  SPEAKER_00: The main uncertainty concerns high chronic intake and individual metabolic or microbiome responses, not a proven direct toxic effect on the optic nerve.
• 1:41
  SPEAKER_00: How glaucoma physiology relates to sweeteners.
• 1:44
  SPEAKER_00: Glaucoma involves progressive loss of retinal ganglion cells and their optic nerve axons.
• 1:50
  SPEAKER_00: Elevated intraocular pressure is the most important modifiable risk factor, but some patients continue to lose retinal tissue even when pressure is adequately controlled.
• 2:00
  SPEAKER_00: This has led to increased interest in blood flow, endothelial function, mitochondrial injury, and immune signaling.
• 2:07
  SPEAKER_00: Endothelial function and ocular blood flow.
• 2:10
  SPEAKER_00: The vascular endothelium regulates vessel tone, blood flow, permeability, inflammation, and nitric oxide signaling.
• 2:18
  SPEAKER_00: Studies of primary open-angle glaucoma have reported systemic vascular abnormalities, including impaired peripheral endothelial function and possible involvement of nitric oxide-related pathways.
• 2:30
  SPEAKER_00: These observations are particularly relevant to normal tension glaucoma and other forms in which optic nerve injury occurs at relatively modest eye pressures.
• 2:40
  SPEAKER_00: Still, brachial artery flow-mediated dilation is not the same as blood flow at the optic nerve head.
• 2:47
  SPEAKER_00: A change in systemic vascular function does not automatically cause a change in ocular perfusion, and a laboratory effect on endothelial cells does not establish glaucoma risk.
• 2:58
  SPEAKER_00: Neuroinflammation and the retinal immune environment.
• 3:01
  SPEAKER_00: The retina contains resident immune cells called microglia, along with astrocytes and Miller cells.
• 3:08
  SPEAKER_00: Under chronic stress, these cells can release inflammatory mediators such as tumor necrosis factor alpha, interleukin-1 beta, interleukin-6, complement-related proteins, and other signaling molecules.
• 3:20
  SPEAKER_00: Persistent glial activation may amplify retinal ganglion cell injury.
• 3:24
  SPEAKER_00: The blood retinal barrier normally limits exposure of retinal tissue to circulating substances and inflammatory cells.
• 3:32
  SPEAKER_00: Barrier disruption can increase vascular leakage and create a more inflammatory environment, but evidence that dietary sweeteners disrupt this barrier in living human eyes is currently lacking.
• 3:43
  SPEAKER_00: Basic pharmacology of the four sweeteners.
• 3:46
  SPEAKER_00: For the full table, please open this article on visualfieldtest.com.
• 3:52
  SPEAKER_00: The United States Food and Drug Administration lists the thresholds above and distinguishes high-purity stevial glycosides from crude stevia leaf products.
• 4:01
  SPEAKER_00: The World Health Organization Joint Food and Agriculture Organization, World Health Organization Expert Committee on Food Additives, uses a lower aspartame threshold of 40 mg per kilogram per day, while its table for saccharin, sucralose, and stevial glycosides lists 15,5 and 4 mg per kilogram per day, respectively.
• 4:22
  SPEAKER_00: Aspartame absorption and metabolism.
• 4:25
  SPEAKER_00: Aspartame is a small methyl ester made from two amino acids.
• 4:29
  SPEAKER_00: It is rapidly broken down in the digestive tract into phenylalanine, aspartic acid, methanol.
• 4:36
  SPEAKER_00: The Joint Food and Agriculture Organization, World Health Organization, Expert Committee on Food Additives concluded that intact aspartame does not enter the systemic circulation in meaningful amounts.
• 4:47
  SPEAKER_00: Its metabolites are the same or chemically similar to substances obtained from ordinary foods.
• 4:53
  SPEAKER_00: This is important for glaucoma risk assessment.
• 4:56
  SPEAKER_00: A cell experiment in which retinal neurons are exposed directly to aspartame does not reproduce ordinary human exposure if intact aspartame is absent from the blood.
• 5:07
  SPEAKER_00: The biologically relevant question would be whether phenylalanine, aspartic acid, methanol, or their downstream products reach the retina at harmful concentrations.
• 5:17
  SPEAKER_00: People with phenylketinuria, a rare inherited disorder of phenylalanine metabolism, should avoid or strictly limit aspartame according to medical guidance.
• 5:27
  SPEAKER_00: This is a specific metabolic condition, not evidence that ordinary aspartame intake causes glaucoma in the general population.
• 5:34
  SPEAKER_00: Endothelial effects.
• 5:36
  SPEAKER_00: Direct human studies linking aspartame with impaired vascular endothelial function are limited.
• 5:41
  SPEAKER_00: In one laboratory model, using glomerular microvascular endothelial cells, aspartame did not reduce cell viability and, at selected concentrations, helped reduce vascular leakage caused by vascular endothelial growth factor.
• 5:56
  SPEAKER_00: This finding should not be interpreted as an eye benefit.
• 5:59
  SPEAKER_00: The cells were kidney derived, the experiment was performed outside the body, and the vascular stimulus was artificial.
• 6:06
  SPEAKER_00: The more clinically relevant comparison is with sugar.
• 6:10
  SPEAKER_00: Sugar-sweetened beverages can cause acute glucose elevations that increase oxidative stress and impair systemic endothelial function.
• 6:19
  SPEAKER_00: Replacing those beverages with a non-caloric option may therefore reduce vascular stress, even if the sweetener itself has no special protective effect.
• 6:28
  SPEAKER_00: Neuroinflammatory and retinal signals.
• 6:31
  SPEAKER_00: Animal studies have reported oxidative stress, inflammatory signaling, and changes in brain tissue after relatively high or prolonged aspartame exposure.
• 6:41
  SPEAKER_00: Findings have included increased tumor necrosis factor alpha, interleukin-1 beta, interleukin-6, nuclear factor kappa B signaling, inducible nitric oxide synthase, and glial fibrillary acidic protein.
• 6:54
  SPEAKER_00: These findings demonstrate biological activity in experimental models, but they do not show that ordinary human intake damages retinal ganglion cells.
• 7:03
  SPEAKER_00: A recent retinal study is mechanistically interesting because aspartame increased intracellular calcium in isolated rat retinal neurons, and saccharin produced a similar effect.
• 7:14
  SPEAKER_00: Excessive intracellular calcium can contribute to neuronal injury in several neurodegenerative diseases.
• 7:21
  SPEAKER_00: However, the experiment used isolated retinal cells exposed directly to sweeteners, not living animals with glaucoma, and direct exposure to intact aspartame does not mirror its normal human pharmacokinetics.
• 7:33
  SPEAKER_00: Overall assessment of aspartame.
• 7:36
  SPEAKER_00: Potential harm?
• 7:37
  SPEAKER_00: Biologically plausible, only in a limited, indirect sense.
• 7:41
  SPEAKER_00: High-dose animal studies and isolated retinal cell findings justify continued research but do not establish a dietary glaucoma hazard.
• 7:49
  SPEAKER_00: Potential benefit, possible when used instead of sugar-sweetened beverages, particularly if it lowers total sugar intake.
• 7:56
  SPEAKER_00: Most likely interpretation at ordinary intake, neutral with respect to glaucoma, provided the person does not have phenylketinuria and intake remains within established limits.
• 8:08
  SPEAKER_00: Sucralose absorption and metabolism.
• 8:11
  SPEAKER_00: Sucralose is a chlorinated derivative of sucrose.
• 8:14
  SPEAKER_00: It is approximately 600 times sweeter than sugar, allowing very small quantities to provide sweetness.
• 8:20
  SPEAKER_00: In a human pharmacokinetic study, approximately 78% of a radio-labeled dose was recovered in feces and approximately 14.5% in urine.
• 8:30
  SPEAKER_00: The material in feces was essentially unchanged sucralose.
• 8:34
  SPEAKER_00: Most urinary material was also sucralose, with only a small fraction represented by more polar, probably conjugated metabolites.
• 8:43
  SPEAKER_00: This means that sucralose is not simply inert, but it is also not extensively metabolized into large quantities of reactive compounds.
• 8:51
  SPEAKER_00: Its strongest potential biological pathway may be through intestinal taste receptors, gut microbial interactions, and metabolic signal, rather than direct delivery to retinal tissue.
• 9:02
  SPEAKER_00: Endothelial effects.
• 9:04
  SPEAKER_00: The available human vascular evidence does not show a consistent direct endothelial injury signal.
• 9:10
  SPEAKER_00: An acute study found that sucralose did not alter brachial artery flow-mediated dilation, and another study in older adults found no acute effect of intestinal sucralose administration on blood pressure or superior mesenteric artery blood flow.
• 9:25
  SPEAKER_00: These studies were small and short-term, but they do not support a strong immediate vascular toxicity signal.
• 9:32
  SPEAKER_00: In a laboratory model of glomerular endothelial cells, sucralose reduced vascular leakage caused by vascular endothelial growth factor and maintained surface expression of vascular endothelial cadharin.
• 9:44
  SPEAKER_00: Sucralose was not detected inside the endothelial cells, suggesting an extracellular receptor-mediated effect.
• 9:51
  SPEAKER_00: Again, this was a kidney cell model and cannot be considered evidence that sucralose protects the retinal circulation.
• 9:58
  SPEAKER_00: Neuroinflammatory signaling A 2024 study exposed a human microglial cell line to sucralose concentrations ranging from 0 to 50 millimolar for short periods and to 1 millimolar for up to 21 days.
• 10:12
  SPEAKER_00: Long-term exposure increased inucin 1 beta, NOD-like receptor protein 3, melondialdehyde, oxidative DNA damage, and caspase activity, while reducing sertuin-1, glutathione, and glutathione peroxidase 4.
• 10:26
  SPEAKER_00: The authors interpreted this pattern as microglial activation, neuroinflammation, and feroptosis.
• 10:33
  SPEAKER_00: This is a potentially relevant pathway because node-like receptor protein 3 signaling and chronic microglial activation are being studied in glaucoma.
• 10:42
  SPEAKER_00: However, the experiment was performed in isolated cells, not in the retina of a person consuming sucralose.
• 10:48
  SPEAKER_00: The study also does not establish that the tested concentrations occur in retinal tissue after ordinary dietary intake.
• 10:56
  SPEAKER_00: Human research has raised a separate concern.
• 10:58
  SPEAKER_00: Responses to sucralose may depend on the gut microbiome and the individual's baseline metabolism.
• 11:05
  SPEAKER_00: In a randomized study of 120 adults, two weeks of sacchar or sucralose supplementation altered glucose tolerance in a person-dependent manner, with microbiome changes appearing to help explain the variation.
• 11:18
  SPEAKER_00: This suggests a possible route from intestinal exposure to systemic inflammation or metabolic stress, but it does not demonstrate optic nerve injury.
• 11:27
  SPEAKER_00: Overall assessment of sucralose.
• 11:30
  SPEAKER_00: Potential harm.
• 11:31
  SPEAKER_00: The strongest concern is indirect and gut-mediated, supported mainly by cell studies and short-term metabolic research.
• 11:39
  SPEAKER_00: Potential benefit: it may reduce glucose-related vascular stress when used to replace sugar.
• 11:44
  SPEAKER_00: Most likely interpretation at ordinary intake.
• 11:47
  SPEAKER_00: Probably neutral for glaucoma, with greater uncertainty among people consuming large amounts chronically or who experience adverse metabolic effects.
• 11:56
  SPEAKER_00: Saccharin absorption and metabolism.
• 11:59
  SPEAKER_00: Saccharin differs substantially from sucralose.
• 12:03
  SPEAKER_00: Human pharmacokinetic research suggests that approximately 85% of an oral dose may be absorbed.
• 12:09
  SPEAKER_00: It is cleared rapidly through the kidneys, with the absorbed dose recovered largely unchanged in urine.
• 12:15
  SPEAKER_00: Because saccharin reaches the circulation more readily than sucralose and is not extensively metabolized, it has a more straightforward route to systemic tissues.
• 12:25
  SPEAKER_00: That does not mean that it reaches the optic nerve at harmful levels, but it makes systemic exposure biologically easier to demonstrate.
• 12:33
  SPEAKER_00: Endothelial effects.
• 12:35
  SPEAKER_00: In vitro studies of glomerular microvascular endothelial cells found that saccharin could reduce vascular leakage induced by vascular endothelial growth factor and preserve vascular endothelial cadin.
• 12:48
  SPEAKER_00: The effect appeared to involve sweet taste receptor signaling rather than intracellular accumulation.
• 12:54
  SPEAKER_00: These findings show that sacchar is capable of interacting with endothelial cells, but they do not establish whether the interaction is beneficial or harmful in the human retinal circulation.
• 13:06
  SPEAKER_00: Human studies directly examining saccharin and endothelial function are sparse.
• 13:11
  SPEAKER_00: There is no convincing clinical evidence that ordinary saccharin intake causes endothelial dysfunction that translates into glaucoma progression.
• 13:20
  SPEAKER_00: Neuroinflammatory and retinal signals.
• 13:23
  SPEAKER_00: Saccharin increased intracellular calcium in isolated rat retinal neurons in the same recent study that examined aspartame.
• 13:31
  SPEAKER_00: This is one of the few experiments directly involving retinal neurons and therefore deserves attention.
• 13:37
  SPEAKER_00: Nevertheless, it has several important limitations.
• 13:40
  SPEAKER_00: It was performed in isolated cells, it did not use a glaucoma model, it did not demonstrate retinal ganglion cell death.
• 13:47
  SPEAKER_00: It did not establish that the concentrations used occur in human retinal tissue.
• 13:52
  SPEAKER_00: It did not measure visual function or glaucoma progression.
• 13:56
  SPEAKER_00: Saccharin has also been included in human microbiome research, in which some participants developed altered glucose responses.
• 14:03
  SPEAKER_00: That finding may be relevant to long-term vascular health, but it remains several biological steps removed from glaucoma.
• 14:11
  SPEAKER_00: Overall assessment of saccharin.
• 14:14
  SPEAKER_00: Potential harm.
• 14:15
  SPEAKER_00: More direct systemic exposure and a retinal cell calcium signal make saccharin mechanistically worth studying, but the evidence remains preclinical.
• 14:23
  SPEAKER_00: Potential benefit its main possible benefit is replacing sugar, not a direct neuroprotective effect.
• 14:29
  SPEAKER_00: Most likely interpretation at ordinary intake, neutral or uncertain, rather than established harmful.
• 14:35
  SPEAKER_00: Stevia and steviol glycosides.
• 14:38
  SPEAKER_00: Important terminology stevia may refer to very different products.
• 14:43
  SPEAKER_00: Commercial foods usually contain purified steviol glycosides, such as steviocide or ribotiocide A.
• 14:50
  SPEAKER_00: Crude stevia leaf and unrefined extracts are chemically more complex.
• 14:54
  SPEAKER_00: The United States Food and Drug Administration has not treated crude stevia leaf or crude extracts, as generally recognized as safe for use as sweeteners in the same way as high purity steviol glycosides.
• 15:06
  SPEAKER_00: Absorption and metabolism.
• 15:08
  SPEAKER_00: Steviol glycosides are not broken down by normal digestive enzymes in the upper digestive tract and are not substantially absorbed there.
• 15:16
  SPEAKER_00: Gut bacteria convert them into steviol in the colon.
• 15:19
  SPEAKER_00: Steviol is then absorbed, converted in the liver mainly to steviol glucuronide, and eliminated through urine and feces.
• 15:27
  SPEAKER_00: In a human study involving people with type 2 diabetes, steviol and steviol glucuronide reached their highest concentrations approximately 19 to 20 hours after a large oral dose of ribodiocide A.
• 15:40
  SPEAKER_00: A single dose did not significantly change glucose, insulin, or C-peptide responses.
• 15:46
  SPEAKER_00: This delayed metabolism makes steviol glycosides different from aspartame and saccharin.
• 15:51
  SPEAKER_00: Their biological effects may depend more on the gut microbiome and the activity of steviol-related metabolites than on direct exposure to the original sweetener.
• 16:01
  SPEAKER_00: Endothelial and cardiovascular effects.
• 16:04
  SPEAKER_00: Steviol glycosides have produced mixed cardiovascular findings.
• 16:08
  SPEAKER_00: Some studies of steviocides suggest modest reductions in blood pressure or fasting glucose, whereas rebodiocyte A has generally shown little effect on cardiovascular risk factors in human trials.
• 16:20
  SPEAKER_00: A systematic review found that the evidence was heterogeneous and that any benefits were small and not robust enough to establish stevia as a cardiovascular treatment.
• 16:30
  SPEAKER_00: A blood pressure or glucose benefit could theoretically support ocular perfusion and vascular health, but this remains speculative.
• 16:39
  SPEAKER_00: There is no clinical trial showing that stevia improves optic nerve blood flow, protects retinal ganglion cells, or slows glaucoma.
• 16:47
  SPEAKER_00: Anti-inflammatory signaling.
• 16:49
  SPEAKER_00: Steviocide has shown anti-inflammatory effects in macrophages and mice.
• 16:54
  SPEAKER_00: Reported pathways include activation of adenosine monophosphate-activated protein kinase and suppression of interferon regulatory factor 5 and nuclear factor kappa B signaling, with reductions in tumor necrosis factor alpha, interleukin-1 beta, interleukin-6 cyclooxygenase 2, and inducible nitric oxide synthase.
• 17:14
  SPEAKER_00: Other animal studies have reported reduced oxidative stress and inflammatory markers in brain tissue after stevia extract administration.
• 17:22
  SPEAKER_00: These findings create a plausible protective hypothesis, but they involve animal disease models, extracts, or doses that may not resemble the purified stevial glycosides used in ordinary foods.
• 17:34
  SPEAKER_00: They also do not specifically address glaucoma.
• 17:37
  SPEAKER_00: Overall assessment of stevia.
• 17:40
  SPEAKER_00: Potential harm?
• 17:41
  SPEAKER_00: Low direct ocular plausibility for purified stevial glycosides, although the long-term effects of different products and mixtures are not identical.
• 17:49
  SPEAKER_00: Potential benefit.
• 17:51
  SPEAKER_00: A modestly favorable metabolic or anti-inflammatory effect is biologically plausible, but not proven for glaucoma.
• 17:58
  SPEAKER_00: Most likely interpretation at ordinary intake, neutral to possibly modestly favorable, particularly when used instead of sugar, but not a glaucoma treatment.
• 18:08
  SPEAKER_00: Neuroinflammation and the gut-brain-eye connection.
• 18:12
  SPEAKER_00: The four sweeteners may differ less in their direct effects on the eye than in their effects on the intestine, microbiome, glucose regulation, and systemic inflammatory state.
• 18:22
  SPEAKER_00: A randomized human study found that responses to aspartame, saccharin, sucralose, and stevia varied between individuals.
• 18:30
  SPEAKER_00: Sacarin and sucralose were associated with altered glucose responses in some participants, and the investigators showed that microbiome changes could help transfer these effects to experimental animals.
• 18:42
  SPEAKER_00: The findings are important but should not be overstated.
• 18:45
  SPEAKER_00: The study measured glucose tolerance, not glaucoma, visual fields, retinal nerve fiber thickness, or optic nerve damage.
• 18:53
  SPEAKER_00: For glaucoma, a plausible chain would be a sweetener alters the gut microbiome or glucose regulation.
• 19:00
  SPEAKER_00: This increases systemic inflammation, oxidative stress, or vascular dysfunction.
• 19:05
  SPEAKER_00: These changes impair ocular perfusion or weaken retinal support cells.
• 19:10
  SPEAKER_00: A vulnerable optic nerve becomes more susceptible to pressure or vascular stress.
• 19:14
  SPEAKER_00: That chain is biologically possible, but it has not been demonstrated in humans.
• 19:19
  SPEAKER_00: The evidence currently supports mechanistic investigation, not a clinical conclusion that any of these sweeteners causes glaucoma.
• 19:28
  SPEAKER_00: Toxicology thresholds and real-world intake.
• 19:31
  SPEAKER_00: Regulatory thresholds.
• 19:32
  SPEAKER_00: For a 60 kilogram adult, the United States Food and Drug Administration thresholds correspond approximately to.
• 19:39
  SPEAKER_00: For the full table, please open this article on VisualFieldTest.com.
• 19:44
  SPEAKER_00: These are lifetime daily exposure limits with built-in safety factors, not targets or recommended amounts.
• 19:51
  SPEAKER_00: The amount of finished product needed to reach them varies because products contain different concentrations and combinations of sweeteners.
• 19:59
  SPEAKER_00: The Food and Drug Administration's illustrative estimate suggests that a 60 kilogram adult would need approximately 75 aspartame packets, 23 sucralose packets, 45 saccharin packets, or 27 roboticocyte A packets in one day to reach the agency's respective thresholds.
• 20:17
  SPEAKER_00: For Aspartame, the Joint Food and Agriculture Organization, World Health Organization Expert Committee on Food Additives, uses a lower threshold of 40 mg per kilogram per day.
• 20:30
  SPEAKER_00: It estimated average exposure up to approximately 5 mg per kilogram per day in adults, and high exposure up to approximately 12 mg per kilogram per day.
• 20:40
  SPEAKER_00: Corresponding estimates for children were higher, but remained below the threshold in its assessment.
• 20:47
  SPEAKER_00: Actual intake.
• 20:48
  SPEAKER_00: Current United States estimates suggest that aspartame exposure is common, but generally below the Food and Drug Administration's acceptable daily intake.
• 20:57
  SPEAKER_00: A recent analysis estimated that 62.6% of the United States population had some exposure and found that mean, 90th percentile, and 95th percentile intakes were below the regulatory threshold.
• 21:11
  SPEAKER_00: For perspective, the World Health Organization reported that a 70-kilogram adult would generally need to consume more than approximately 9 to 14 cans of a diet soft drink containing 200 to 300 milligrams of aspartame per can to exceed the Joint Food and Agriculture Organization World Health Organization threshold from that source alone.
• 21:34
  SPEAKER_00: This calculation excludes other dietary sources and is not a recommendation to consume that amount.
• 21:57
  SPEAKER_00: However, these estimates are sensitive to product formation.
• 22:00
  SPEAKER_00: Stimulation, brand loyalty, serving size, and whether sweeteners are consumed in foods rather than beverages.
• 22:07
  SPEAKER_00: Urinary biomarker research also shows that people commonly consume mixtures of low and no-calorie sweeteners.
• 22:14
  SPEAKER_00: Sucralose can be difficult to estimate from urine because most of it is eliminated through feces, whereas sacchin and steviol-related metabolites are more readily measured in urine.
• 22:25
  SPEAKER_00: Comparative judgment, harm, benefit, or neutrality.
• 22:29
  SPEAKER_00: For the full table, please open this article on visualfieldtest.com.
• 22:33
  SPEAKER_00: What this means for a person with glaucoma, do not treat glaucoma with dietary sweeteners.
• 22:39
  SPEAKER_00: No sweetener has been shown to lower intraocular pressure, protect the optic nerve in humans, or replace glaucoma medication, laser treatment, or surgery.
• 22:49
  SPEAKER_00: Monitoring eye pressure, optic nerve structure, visual fields, and treatment adherence remains far more important than choosing one sweetener over another.
• 22:57
  SPEAKER_00: Replacing sugar is different from adding sweeteners.
• 23:01
  SPEAKER_00: The most credible health benefit comes from substitution.
• 23:04
  SPEAKER_00: Replacing a sugar-sweetened beverage with water or an unsweetened drink is generally preferable.
• 23:10
  SPEAKER_00: If a low-calorie sweetener helps someone stop drinking large amounts of sugar-sweetened beverages, the overall metabolic effect may be favorable even if the sweetener itself is biologically neutral.
• 23:23
  SPEAKER_00: Sugar-sweetened beverages have more established links to glucose excursions and endothelial dysfunction than these four sweeteners have to glaucoma.
• 23:31
  SPEAKER_00: Avoid assuming that natural means protective.
• 23:36
  SPEAKER_00: Purified stevial glycosides have a reassuring safety profile and some favorable experimental findings, but natural does not prove benefit.
• 23:44
  SPEAKER_00: Whole leaf products, concentrated extracts, and products containing multiple sweeteners or sugar alcohols may not behave identically.
• 23:52
  SPEAKER_00: Pay attention to individual responses.
• 23:54
  SPEAKER_00: Some people experience headaches, gastrointestinal symptoms, appetite changes, or perceived blood glucose effects with particular products.
• 24:02
  SPEAKER_00: These responses do not necessarily indicate retinal toxicity, but they may be a reason to choose water or unsweetened beverages instead.
• 24:11
  SPEAKER_00: Conclusion.
• 24:12
  SPEAKER_00: Aspartame, sucralose, saccharin, and stevial glycosides differ substantially in their absorption and metabolism.
• 24:19
  SPEAKER_00: Aspartame is digested into ordinary dietary metabolites rather than circulating intact.
• 24:25
  SPEAKER_00: Sucralose is mostly eliminated unchanged, with potential biological effects occurring through the intestine and microbiome.
• 24:32
  SPEAKER_00: Saccharin is substantially absorbed and rapidly excreted, making systemic exposure more direct.
• 24:38
  SPEAKER_00: Stevial glycosides are converted by gut bacteria into steviol and then steviol glucurinide, with preclinical evidence that is often anti-inflammatory but not glaucoma-specific.
• 24:50
  SPEAKER_00: The most relevant experimental concerns are retinal cell calcium signaling with aspartame and saccharin, microglial inflammatory signaling with high concentration sucralose, and possible anti-inflammatory effects of stevial glycosides.
• 25:04
  SPEAKER_00: None of these findings has been shown to cause or prevent glaucoma in humans.
• 25:09
  SPEAKER_00: Through the lens of ocular physiology, the best supported position is that ordinary consumption within established toxicology limits is probably neutral for glaucoma.
• 25:20
  SPEAKER_00: A potential indirect benefit exists when these products replace large quantities of sugar, while the possibility of harm becomes more plausible, but still unproven, with very high chronic intake, adverse metabolic responses, or consumption as part of an overall poor quality diet.
• 25:37
  SPEAKER_00: All links to sources are available in the text version of this article.
• 25:41
  SPEAKER_00: You can find the full article at visualfieldtest.com.
• 25:45
  SPEAKER_00: Thanks for listening.
• 25:46
  SPEAKER_00: To check your visual field, click the link at the bottom of this article or visit visualfieldtest.com.